Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Google Secures Pentagon AI Deal for Classified Projects 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
IRVINE, Calif., April 19, 2017 -- Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Lion Biotechnologies, Inc. (“Lion” or the “Company”) (Nasdaq:LBIO). Investors who purchased or otherwise acquired shares between November 14, 2013 and April 10, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the June 13, 2017 lead plaintiff motion deadline.
If you purchased shares of Lion during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
The Complaint states that throughout the Class Period, Lion made false and/or misleading statements and/or failed to disclose: that Lion, through its former CEO Manish Singh, engaged in a scheme to mislead investors by commissioning over 10 internet publications and 20 widely distributed emails promoting Lion to potential investors that purported to be independent from the company when, in fact, they were paid promotions; that former CEO Singh engaged a notorious stock promotion firm to pay writers to publish articles about the Company on investment websites and to coordinate the distribution of articles to thousands of electronic mailboxes; that former CEO Singh actively participated in the promotional work for Lion Biotechnologies and understood that the promotion firm was using writers who would not disclose that Lion was indirectly compensating them for their publications; and that as a result of the above, Lion’s public statements were materially false and misleading at all relevant times. When this news was released, shares of Lion declined in value.
If you wish to learn more about this lawsuit, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
